Companies › Hangzhou Zhongmei Huadong Pharmaceutical
12 active drug programs in 25 registered trials: 15 Phase 1, 5 Phase 3, 3 Phase 2, 2 Phase 4; Oncology, Metabolic and endocrine, Gastroenterology, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ganagliflozin SGLT-2 inhibitor | SLC5A2 | Phase 4 | T2DM (Type 2 Diabetes Mellitus) | Dec 2027 |
| liraglutide Glucagon-like peptide 1 receptor agonist | GLP1R | Phase 4 | T2DM (Type 2 Diabetes Mellitus) | Dec 2027 |
| HDM1005 injection GLP-1 receptor agonist | GLP1R | Phase 3 | Obesity & Overweight; Type 2 Diabetes; Obesity; Overweight and/or Obesity | Nov 2026 |
| HDM1002 | – | Phase 3 | Type 2 Diabetes; Overweight Subject; Hepatic Impairment; Healthy Adult Subject | Feb 2027 |
| HDM1702 GLP-1 receptor agonist | – | Phase 3 | Obesity Control | – |
| HDM2017 | – | Phase 1 | Solid Tumors; CRC, Colorectal Cancer | Dec 2026 |
| HDP-101 | – | Phase 1 | Multiple Myeloma and Other Plasma Cell Neoplasms | Dec 2026 |
| HDM2020 FGFR2b-targeted antibody-drug conjugate | FGFR2 | Phase 1 | Squamous Non-small Cell Lung Cancer(NSCLC); Solid Tumor | Jan 2027 |
| HDM2006 | – | Phase 1 | Advanced Solid Tumors | Mar 2027 |
| HDM2024 Antibody-drug conjugate targeting EGFR and HER3 | EGFR, HER3 | Phase 1 | Advanced Solid Tumors | Apr 2027 |
| HDM2005 PROTAC-mediated MDM2 degradation | – | Phase 1 | Advanced Solid Tumors; Diffuse Large B Cell Lymphoma (DLBCL) | Jul 2027 |
| HDM2012 | – | Phase 1 | Advanced Solid Tumors | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06886126 | HDM1005 injection | Phase 2 | Obesity | Metabolic and endocrine | Sep 2025 |
| NCT07331389 | HDM1002 | Phase 1 | Overweight Subject | Metabolic and endocrine | Jan 2026 |
| NCT06985615 | HDM1002 | Phase 1 | Hepatic Impairment | Gastroenterology | Jan 2026 |
| NCT07109700 | HDM1005 injection | Phase 2 | Type 2 Diabetes | Metabolic and endocrine | Jan 2026 |
| NCT07036172 | HDM1702 | Phase 3 | Obesity Control | Metabolic and endocrine | Apr 2026 |
| NCT07594847 | HDM1002 | Phase 1 | Healthy Adult Subject | Other | Sep 2026 |
| NCT07828197 | HDM1005 injection | Phase 1 | Overweight and/or Obesity | Metabolic and endocrine | Nov 2026 |
| NCT07279194 | HDM1005 injection | Phase 3 | Obesity & Overweight | Metabolic and endocrine | Dec 2026 |
| NCT07529782 | HDP-101 | Phase 1 | Multiple Myeloma and Other Plasma Cell Neoplasms | Oncology | Dec 2026 |
| NCT07274085 | HDM2017 | Phase 1 | Solid Tumors | Oncology | Dec 2026 |
| NCT07638891 | HDM2020 | Phase 1 | Squamous Non-small Cell Lung Cancer(NSCLC) | Oncology | Jan 2027 |
| NCT07193459 | HDM1002 | Phase 3 | Type 2 Diabetes | Metabolic and endocrine | Feb 2027 |
| NCT07521631 | HDM1005 injection | Phase 2 | Obesity | Metabolic and endocrine | Feb 2027 |
| NCT07082114 | HDM1002 | Phase 3 | Type 2 Diabetes | Metabolic and endocrine | Feb 2027 |
| NCT07377591 | HDM2006 | Phase 1 | Advanced Solid Tumors | Oncology | Mar 2027 |
| NCT07539285 | HDM2024 | Phase 1 | Advanced Solid Tumors | Oncology | Apr 2027 |
| NCT07098052 | HDM2020 | Phase 1 | Solid Tumor | Oncology | May 2027 |
| NCT07004296 | HDM2005 | Phase 1 | Advanced Solid Tumors | Oncology | Jul 2027 |
| NCT07394114 | HDM1005 injection | Phase 3 | Type 2 Diabetes | Metabolic and endocrine | Aug 2027 |
| NCT07100249 | HDM2012 | Phase 1 | Advanced Solid Tumors | Oncology | Oct 2027 |
| NCT07124936 | HDM2005 | Phase 1 | Diffuse Large B Cell Lymphoma (DLBCL) | Oncology | Oct 2027 |
| NCT07244003 | ganagliflozin | Phase 4 | T2DM (Type 2 Diabetes Mellitus) | Metabolic and endocrine | Dec 2027 |
| NCT07244003 | liraglutide | Phase 4 | T2DM (Type 2 Diabetes Mellitus) | Metabolic and endocrine | Dec 2027 |
| NCT06615193 | HDM2005 | Phase 1 | Advanced Solid Tumors | Oncology | Feb 2028 |
| NCT07805551 | HDM2017 | Phase 1 | CRC, Colorectal Cancer | Oncology | Aug 2030 |
Hanmi Pharmaceutical Company Changchun GeneScience Pharmaceutical Shanghai JMT-Bio Sichuan Baili Pharmaceutical Dong-A ST
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.